Differential impact of ageing on cellular and humoral immunity to a persistent murine γ-herpesvirus

Immunity and Ageing

Volumn 7, Issue , 2010, Pages

  Yager, Eric J ^a   Kim, In Jeong ^b   Freeman, Michael L ^c   Lanzer, Kathleen G ^c   Burkum, Claire E ^c   Cookenham, Tres ^c   Woodland, David L ^c   Blackman, Marcia A ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b PFIZER INC   (United States)

^c TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GAMMAHERPESVIRINAE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LATENCY; VIRUS LOAD; VIRUS NEUTRALIZATION;

EID: 77951243991     PISSN: 17424933     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4933-7-3     Document Type: Article

References (90)

1. Pawelec G, Larbi A. Immunity and ageing in man: Annual Review 2006/2007. Exp Gerontol 2008, 43(1):34-38.
2. Cambier J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev 2005, 205:5-6. 10.1111/j.0105-2896.2005.00276.x, 15882340.
3. Murasko DM, Jiang J. Response of aged mice to primary virus infections. Immunol Rev 2005, 205:285-296. 10.1111/j.0105-2896.2005.00273.x, 15882361.
4. Haynes L, Eaton SM. The effect of age on the cognate function of CD4+ T cells. Immunol Rev 2005, 205:220-228. 10.1111/j.0105-2896.2005.00255.x, 2577194, 15882356.
5. Haynes L, Cambier J, Fulder R. Aging and immune function. Summary of a workshop held at Trudeau Institute, Saranac Lake, NY. Mech Ageing Dev 2005, 126(6-7):822-825. 10.1016/j.mad.2005.02.007, 15981319.
6. Weller TH. Varicella: historical perspective and clinical overview. J Infect Dis 1996, 174(Suppl 3):S306-309.
7. Rickinson AB, Kieff E. Epstein-Barr Virus. Fields Virology 2001, 2575-2627. Philadelphia: Lippincott Williams and Wilkins, DM Knipe PMH.
8. Pagano JS. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians 1999, 111(6):573-580. 10.1046/j.1525-1381.1999.t01-1-99220.x, 10591086.
9. Sarid R, Olsen SJ, Moore PS. Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res 1999, 52:139-232. full_text, 10384236.
10. Blackman MA, Flano E, Usherwood E, Woodland DL. Murine γ-herpesvirus-68: a mouse model for infectious mononucleosis?. Mol Med Today 2000, 6:488-490. 10.1016/S1357-4310(00)01813-X, 11099955.
11. Doherty PC, Christensen JP, Belz GT, Stevenson PG, Sangster MY. Dissecting the host response to a gamma-herpesvirus. Philos Trans R Soc Lond B Biol Sci 2001, 356(1408):581-593. 10.1098/rstb.2000.0786, 1088446, 11313013.
12. Nash AA, Dutia BM, Stewart JP, Davison AJ. Natural history of murine gammaherpesvirus infection. Philos Trans R Soc Lond B Biol Sci 2001, 356:569-579. 10.1098/rstb.2000.0779, 1088445, 11313012.
13. Blackman MA, Flano E. Persistent gamma-herpesvirus infections: what can we learn from an experimental mouse model?. J Exp Med 2002, 195(7):F29-32. 10.1084/jem.20020243, 2193722, 11927639.
14. Virgin HW, Latreille P, Wamsley P, Hallsworth K, Weck KE, Dal Canto AJ, Speck SH. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol 1997, 71(8):5894-5904. 191845, 9223479.
15. Flano E, Jia Q, Moore J, Woodland DL, Sun R, Blackman MA. Early Establishment of {gamma}-Herpesvirus Latency: Implications for Immune Control. J Immunol 2005, 174(8):4972-4978.
16. Sunil-Chandra NP, Efstathiou S, Nash AA. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J Gen Virol 1992, 73(Pt 12):3275-3279. 10.1099/0022-1317-73-12-3275, 1469366.
17. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996, 184(3):863-871. 10.1084/jem.184.3.863, 2192775, 9064346.
18. Flano E, Husain SM, Sample JT, Woodland DL, Blackman MA. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J Immunol 2000, 165(2):1074-1081.
19. Kim IJ, Flano E, Woodland DL, Blackman MA. Antibody-mediated control of persistent gamma-herpesvirus infection. J Immunol 2002, 168(8):3958-3964.
20. Weck KE, Kim SS, Virgin HW, Speck SH. B cells regulate murine gammaherpesvirus 68 latency. J Virol 1999, 73(6):4651-4661. 112506, 10233924.
21. Usherwood EJ, Ward KA, Blackman MA, Stewart JP, Woodland DL. Latent antigen vaccination in a model gammaherpesvirus infection. J Virol 2001, 75(17):8283-8288. 10.1128/JVI.75.17.8283-8288.2001, 115072, 11483773.
22. Tibbetts SA, Suarez F, Steed AL, Simmons JA, Virgin HW. A gamma-herpesvirus deficient in replication establishes chronic infection in vivo and is impervious to restriction by adaptive immune cells. Virology 2006, 353(1):210-219. 10.1016/j.virol.2006.05.020, 16797052.
23. Ehtisham S, Sunil-Chandra NP, Nash AA. Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. J Virol 1993, 67(9):5247-5252. 237922, 8394447.
24. Gangappa S, Kapadia SB, Speck SH, Virgin HW. Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice. J Virol 2002, 76(22):11460-11468. 10.1128/JVI.76.22.11460-11468.2002, 136779, 12388707.
25. Husain SM, Usherwood EJ, Dyson H, Coleclough C, Coppola MA, Woodland DL, Blackman MA, Stewart JP, Sample JT. Murine gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8(+) T lymphocytes. Proc Nat Acad Sci USA 1999, 96(13):7508-7513. 10.1073/pnas.96.13.7508, 22116, 10377445.
26. Tibbetts S, van Dyk L, Speck S, Virgin HW. Immune control of the number and reactivation phenotype of cells latently infected with gammaherpesvirus. J Virol 2002, 76(14):125-132.
27. Usherwood EJ, Roy DJ, Ward K, Surman SL, Dutia BM, Blackman MA, Stewart JP, Woodland DL. Control of Gammaherpesvirus Latency by Latent Antigen-specific CD8(+) T Cells. J Exp Med 2000, 192(7):943-952. 10.1084/jem.192.7.943, 2193320, 11015436.
28. Virgin HW. Immune regulation of viral infection and vice versa. Immunol Res 2005, 32(1-3):293-315. 10.1385/IR:32:1-3:293, 16106080.
29. Holtappels R, Pahl-Seibert MF, Thomas D, Reddehase MJ. Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol 2000, 74(24):11495-11503. 10.1128/JVI.74.24.11495-11503.2000, 112429, 11090146.
30. Karrer U, Wagner M, Sierro S, Oxenius A, Hengel H, Dumrese T, Freigang S, Koszinowski UH, Phillips RE, Klenerman P. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol 2004, 78(5):2255-2264. 10.1128/JVI.78.5.2255-2264.2004, 369208, 14963122.
31. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 2006, 177(1):450-458.
32. Ely KH, Ahmed M, Kohlmeier JE, Roberts AD, Wittmer ST, Blackman MA, Woodland DL. Antigen-specific CD8+ T cell clonal expansions develop from memory T cell pools established by acute respiratory virus infections. J Immunol 2007, 179(6):3535-3542.
33. Cush SS, Anderson KM, Ravneberg DH, Weslow-Schmidt JL, Flano E. Memory generation and maintenance of CD8+ T cell function during viral persistence. J Immunol 2007, 179(1):141-153.
34. Sangster MY, Topham DJ, D'Costa S, Cardin RD, Marion TN, Myers LK, Doherty PC. Analysis of the virus-specific and nonspecific B cell response to a persistent B-lymphotropic gammaherpesvirus. J Immunol 2000, 164(4):1820-1828.
35. Stevenson PG, Doherty PC. Kinetic analysis of the specific host response to a murine gammaherpesvirus. J Virol 1998, 72(2):943-949. 124564, 9444986.
36. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9(9):1131-1137. 10.1038/nm917, 12925846.
37. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171(10):4969-4973.
38. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008, 455(7212):532-536. 10.1038/nature07231, 18716625.
39. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. J Exp Med 2005, 202(1):123-133. 10.1084/jem.20050137, 2212898, 15983064.
40. Kapasi ZF, Murali-Krishna K, McRae ML, Ahmed R. Defective generation but normal maintenance of memory T cells in old mice. Eur J Immunol 2002, 32:1567-1573. 10.1002/1521-4141(200206)32:6<1567::AID-IMMU1567>3.0.CO;2-P, 12115639.
41. Prlic M, Williams MA, Bevan MJ. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr Opin Immunol 2007, 19(3):315-319. 10.1016/j.coi.2007.04.010, 17433873.
42. Williams MA, Holmes BJ, Sun JC, Bevan MJ. Developing and maintaining protective CD8+ memory T cells. Immunol Rev 2006, 211:146-153. 10.1111/j.0105-2896.2006.00389.x, 16824124.
43. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300(5617):337-339. 10.1126/science.1082305, 12690201.
44. Miller RA. The aging immune system: primer and prospectus. Science 1996, 273(5271):70-74. 10.1126/science.273.5271.70, 8658199.
45. Haynes L, Swain SL. Why aging T cells fail: implications for vaccination. Immunity 2006, 24(6):663-666. 10.1016/j.immuni.2006.06.003, 16782020.
46. Haynes L, Linton PJ, Eaton SM, Tonkonogy SL, Swain SL. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J Exp Med 1999, 190(7):1013-1024. 10.1084/jem.190.7.1013, 2195647, 10510091.
47. Haynes L, Eaton SM, Swain SL. The defects in effector generation associated with aging can be reversed by addition of IL-2 but not other related gamma(c)-receptor binding cytokines. Vaccine 2000, 18(16):1649-1653. 10.1016/S0264-410X(99)00501-0, 10689143.
48. Linton PJ, Haynes L, Klinman NR, Swain SL. Antigen-independent changes in naive CD4 T cells with aging. J Exp Med 1996, 184(5):1891-1900. 10.1084/jem.184.5.1891, 2192899, 8920876.
49. Linton PJ, Haynes L, Tsui L, Zhang X, Swain S. From naive to effector--alterations with aging. Immunol Rev 1997, 160:9-18. 10.1111/j.1600-065X.1997.tb01023.x, 9476661.
50. Ouyang Q, Wagner WM, Walter S, Muller CA, Wikby A, Aubert G, Klatt T, Stevanovic S, Dodi T, Pawelec G. An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev 2003, 124(4):477-485. 10.1016/S0047-6374(03)00026-5, 12714256.
51. Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol 2007, 42(6):563-570. 10.1016/j.exger.2007.01.005, 1992441, 17337145.
52. Glaser R, Strain EC, Tarr KL, Holliday JE, Donnerberg RL, Kiecolt-Glaser JK. Changes in Epstein-Barr virus antibody titers associated with aging. Proc Soc Exp Biol Med 1985, 179(3):352-355.
53. Mueller N. Epidemiologic studies assessing the role of the Epstein-Barr virus in Hodgkin's disease. Yale J Biol Med 1987, 60(4):321-332. 2590239, 2821703.
54. Kojima M, Morita Y, Nakamura N, Shimizu K, Murayama K, Nakamura S. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases. Pathol Res Pract 2008, 204(4):267-272. 10.1016/j.prp.2007.11.007, 18187262.
55. Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, Yokoi T, Kojima M, Kamiya Y, Taji H, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 2003, 27(1):16-26. 10.1097/00000478-200301000-00003, 12502924.
56. Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007, 13(17):5124-5132. 10.1158/1078-0432.CCR-06-2823, 17785567.
57. Shimoyama Y, Yamamoto K, Asano N, Oyama T, Kinoshita T, Nakamura S. Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci 2008, 99(6):1085-1091. 10.1111/j.1349-7006.2008.00813.x, 18429953.
58. Shroff R, Rees L. The post-transplant lymphoproliferative disorder-a literature review. Pediatr Nephrol 2004, 19(4):369-377. 10.1007/s00467-003-1392-x, 14986084.
59. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994, 83(9):2715-2722.
60. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994, 84(3):972-984.
61. Kirshner JR, Staskus K, Haase A, Lagunoff M, Ganem D. Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis. J Virol 1999, 73(7):6006-6014. 112661, 10364352.
62. Kimball LE, Casper C, Koelle DM, Morrow R, Corey L, Vieira J. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 2004, 189(11):2016-2022. 10.1086/386371, 15143468.
63. Kamel OW, Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994, 25(7):638-643. 10.1016/0046-8177(94)90295-X, 8026822.
64. Paul C, Le Tourneau A, Cayuela JM, Devidas A, Robert C, Molinie V, Dubertret L. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 1997, 133(7):867-871. 10.1001/archderm.133.7.867, 9236525.
65. Kamel OW, Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, Montgomery PG, Warnke RA, Dorfman RF. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993, 328(18):1317-1321. 10.1056/NEJM199305063281806, 8385742.
66. Fahey JL, Sell S. The Immunoglobulins of Mice. V. The Metabolic (Catabolic) Properties of Five Immunoglobulin Classes. J Exp Med 1965, 122:41-58. 10.1084/jem.122.1.41, 2138025, 14330751.
67. Talbot PJ, Buchmeier MJ. Catabolism of homologous murine monoclonal hybridoma IgG antibodies in mice. Immunology 1987, 60(4):485-489. 1453269, 3034767.
68. Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 1988, 18(2):313-316. 10.1002/eji.1830180221, 3350037.
69. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996, 272(5258):54-60. 10.1126/science.272.5258.54, 8600537.
70. Slifka MK, Ahmed R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol 1996, 4(10):394-400. 10.1016/0966-842X(96)10059-7, 8899965.
71. Slifka MK. Immunological memory to viral infection. Curr Opin Immunol 2004, 16(4):443-450. 10.1016/j.coi.2004.05.013, 15245737.
72. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8(3):363-372. 10.1016/S1074-7613(00)80541-5, 9529153.
73. Hyland L, Sangster M, Sealy R, Coleclough C. Respiratory virus infection of mice provokes a permanent humoral immune response. J Virol 1994, 68(9):6083-6086. 237018, 8057487.
74. Ternak G, Szucs G, Uj M. The serological signs of the Epstein-Barr virus (EBV) activity in the elderly. Acta Microbiol Immunol Hung 1997, 44(2):133-140.
75. Sumaya CV. Endogenous reactivation of Epstein-Barr virus infections. J Infect Dis 1977, 135(3):374-379.
76. Kosco MH, Burton GF, Kapasi ZF, Szakal AK, Tew JG. Antibody-forming cell induction during an early phase of germinal centre development and its delay with ageing. Immunology 1989, 68(3):312-318. 1385441, 2592007.
77. Goidl EA, Innes JB, Weksler ME. Immunological studies of aging. II. Loss of IgG and high avidity plaque- forming cells and increased suppressor cell activity in aging mice. J Exp Med 1976, 144(4):1037-1048. 10.1084/jem.144.4.1037, 2190420, 62009.
78. Cook JM, Gualde N, Hessel L, Mounier M, Michel JP, Denis F, Ratinaud MH. Alterations in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol 1987, 109(1):89-96. 10.1016/0008-8749(87)90294-2, 2958144.
79. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986, 154(2):245-256.
80. Phair J, Kauffman CA, Bjornson A, Adams L, Linnemann C. Failure to respond to influenza vaccine in the aged: correlation with B- cell number and function. J Lab Clin Med 1978, 92(5):822-828.
81. Nicoletti C, Cerny J. The repertoire diversity and magnitude of antibody responses to bacterial antigens in aged mice: I. Age-associated changes in antibody responses differ according to the mouse strain. Cell Immunol 1991, 133(1):72-83. 10.1016/0008-8749(91)90180-J, 1991330.
82. Nicoletti C, Cerny J. A study of autologous anti-idiotypic antibody-forming cells in mice of different ages and genetic backgrounds. Cell Immunol 1992, 144(2):332-346. 10.1016/0008-8749(92)90249-O, 1394446.
83. Nicoletti C, Yang X, Cerny J. Repertoire diversity of antibody response to bacterial antigens in aged mice. III. Phosphorylcholine antibody from young and aged mice differ in structure and protective activity against infection with Streptococcus pneumoniae. J Immunol 1993, 150(2):543-549.
84. Miller C, Kelsoe G. Ig VH hypermutation is absent in the germinal centers of aged mice. J Immunol 1995, 155(7):3377-3384.
85. Zheng B, Han S, Takahashi Y, Kelsoe G. Immunosenescence and germinal center reaction. Immunol Rev 1997, 160:63-77. 10.1111/j.1600-065X.1997.tb01028.x, 9476666.
86. Tsiagbe VK, Inghirami G, Thorbecke GJ. The physiology of germinal centers. Crit Rev Immunol 1996, 16(4):381-421.
87. Daly K, Nguyen P, Woodland DL, Blackman MA. Immunodominance of major histocompatibility complex class I-restricted influenza virus epitopes can be influenced by the T-cell receptor repertoire. J Virol 1995, 69(12):7416-7422. 189678, 7494246.
88. Flano E, Kayhan B, Woodland DL, Blackman MA. Infection of dendritic cells by a gamma2-herpesvirus induces functional modulation. J Immunol 2005, 175(5):3225-3234.
89. Weck KE, Barkon ML, Yoo LI, Speck SH, Virgin HW. Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. J Virol 1996, 70(10):6775-6780. 190721, 8794315.
90. Kim IJ, Burkum CE, Cookenham T, Schwartzberg PL, Woodland DL, Blackman MA. Perturbation of B cell activation in SLAM-associated protein-deficient mice is associated with changes in gammaherpesvirus latency reservoirs. J Immunol 2007, 178(3):1692-1701.